Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

Maximum days for report delivery: 14 days

What are the prerequisites for the test ALL Risk Stratification Gene Panel- B-ALL

  • Sample Type: Bone marrow or peripheral blood
  • Sample Volume: 3-5 mL
  • Sample Storage: Refrigerate
  • Shipping Conditions: Ship overnight at room temperature
  • Turnaround Time: 7-10 days
  • Pre-authorization required: No

What are the measure values for the test ALL Risk Stratification Gene Panel- B-ALL

  • BCR/ABL1 (p190) - Negative
  • ETV6/RUNX1 (TEL/AML1) - Negative
  • TCF3/PBX1 (E2A/PBX1) - Negative
  • IKZF1 - Negative
  • PAX5 - Negative
  • CDKN2A/B (p16/p14) - Negative
  • BTG1 - Negative
  • ERG - Negative
  • IL3/IL3RA - Negative
  • FLT3 - Negative

What does this test ALL Risk Stratification Gene Panel- B-ALL identify?

Test: ALL Risk Stratification Gene Panel- B-ALL

This test identifies specific genetic mutations that are associated with a higher risk of developing B-cell acute lymphoblastic leukemia (B-ALL). By analyzing the presence of these mutations, healthcare providers can determine the prognosis and potential treatment options for individuals with B-ALL.

The test results can help classify patients into different risk groups, such as standard-risk, high-risk, or very high-risk, based on the genetic profile of their cancer cells. This information is crucial for guiding treatment decisions and monitoring the response to therapy.

Why is this test ALL Risk Stratification Gene Panel- B-ALL taken?

The ALL Risk Stratification Gene Panel- B-ALL test is taken to help determine the risk stratification of pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL). This test analyzes specific genetic mutations and abnormalities that are associated with different risk levels and treatment outcomes in patients with B-ALL. By identifying these genetic markers, healthcare providers can tailor treatment plans to best suit the individual patient's needs and improve overall prognosis.

No FAQs available.

Customer Google Rating